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This article argues that prizes can help stimulate medical innovation, control costs and
ensure greater access to new medicines and vaccines. The authors explore four
increasingly ambitious prize options to reward medical innovation, each addressing
flaws in the currentpatent system. The first option promotes innovation through a large
prize fund linked to the impact on health outcomes; the second option rewards the
sharing of knowledge, data, and technology with open source dividends; the third
option awards prizes for interim benchmarks and discrete technicalproblems; and the
final option removes the exclusive right to use patented inventions in upstream research
in favor of prizes. The authors conclude that a system of prizes to reward drug
development would break the link between R&D incentives and product prices, and
that such a reform is needed to improve innovation and access to new medicines and
vaccines.
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This article addresses the barriersto personalizedmedicine, focusing on the burgeoning
field of biomarkers research. The author begins by framing intellectual property issues
as more than a product of industry incentives and suggests that these issues are deeply
entangled with other barriers facing personalized medicine such as regulatory
framework deficiencies. The authorproposes a set of future researchquestions to more
fully define the barriers to biomarkers research and to uncover which corrective
measures may be effective. The author concludes by recommending an integration of
regulatory and patent reforms, with a call to action by scholars, scientists,
representativesof the biopharmaceuticalindustry, and policy-makers.
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This article discusses advances in genomic research in the context of the debate
surrounding gene patent rights and the limited rights of patient-participants in
translationalresearch. In addition,the authorexplores statutory and regulatoryhurdles
to advances in disease diagnosis, such the Bayh-Dole Act, Medicare Legislation, and
the Health Insurance Portability and Accountability Act. The author questions the
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effectiveness of increasingly commercialized academic researchand the limited success
of the private sector in genomic research. The author concludes that future genomic
research will requiresignificantly increasedpatient participation,which may necessitate
a reshaping of the pharmaceutical approach to medicine and the limited stake that
patients have in the breakthroughsdeveloped through their participationin the process.
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The authors address how patent protection in the United States is often quite narrow in
scope, difficult to obtain, and insufficient in duration, thus stifling research and
development of potential breakthroughpharmaceuticals. The authorsfurtherposit that
countries that have enacted stronger intellectual property rights and research incentives
have seen tremendous increases in foreign direct investment. In addressingcritics of the
currentpatent system, the authors show that alternatives to biotechnology patents would
not demonstrably improve innovation and development of beneficial medicines. The
authors conclude that given the substantialevidence of the patent system's benefits, and
the mere speculation that patents have a deleterious effect on patients, no suggestions
currentlyproposed to replace or improve the patentsystem will have the same beneficial
effects for patients.
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How to Incentivize Innovation ....... ANN WEILBAECHER, PsY.D.

281
This comment addresses the inadequacies of research and development for diseases
endemic in developing countries and explores how the patent system can inhibit
innovation for new drugs for neglected diseases. The authoranalyzes four strategies to
encourage innovation, including open source initiatives,patent pools, prizes, and wild
card patentextensions, and examines how these alternativesystems may spur innovation
while balancing cost concerns held by drug manufacturers and purchasers. The author
concludes that a combination of solutions may provide the best framework for the
creation of essential medicines for neglected diseases.
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